The recently established international, transdisciplinary Ludwig Boltzmann Institute Applied Diagnostics (LBI AD) in Vienna, Austria, focuses on the development and application of non-invasive dual diagnostic methods (combining molecular epigenetic and genetic signatures and molecular imaging biomarkers) to allow for improved tumour diagnosis and characterisation, and its translation into personalised patient care. The strong link between clinical and basic science related projects researched also from broader social sciences aspects within the institute provides an excellent basis for transdisciplinary research and training.
Professor Judit Simon is one of the key researchers of the LBI AD leading a specific program line on relevant broader socioeconomic research questions. The program line focuses on methodological and applied health economics research questions in the areas of personalised oncology diagnosis and treatment including individual patient-level data analyses, decision analytic modelling, health technology assessment, and value of information analysis in order to support the development of cost-effective test-treatment strategies and to assess their budget impact. Relevant ethical, social and legal considerations are also researched. The program line is further supported by Professor Uwe Siebert and Professor Alena Buyx.
- Stelzer IV, Sierawska A, Buyx A, Simon J. A network-based mixed methods approach to analyze current perspectives on personalized oncological medicine in Austria. J Pers Med. 2020 Dec 12;10(4),276. DOI: 10.3390/jpm10040276
- Grössmann N, Robausch M, Willenbacher W, Wolf S, Simon J, Wild C. Magnitude of Clinical Benefit” of solid tumour drugs and their real-world application in the Austrian health care setting. J Cancer Policy. 2020 Sep;25:100235. DOI: 10.1016/j.jcpo.2020.100235
- Grössmann N, Robausch M, Rothschedl E, Wild C, Simon J. Publicly accessible evidence of health-related quality of life benefits associated with cancer drugs approved by the European Medicines Agency between 2009 and 2015. Eur J Cancer. 2020 Febr 28;129:23-31. DOI: 10.1016/j.ejca.2020.01.020
- Lim MS, Beyer T, Babayan A, Bergmann M, Brehme M, Buyx A, et al. Advancing Biomarker Development Through Convergent Engagement: Summary Report of the 2nd International Danube Symposium on Biomarker Development, Molecular Imaging and Applied Diagnostics; March 14-16, 2018; Vienna, Austria. Mol Imaging Biol. 2019;Special Topic:1-19. DOI: 10.1007/s11307-019-01361-2
- Grössmann, N, Robausch, M, Rosian, K, Wild, C, Simon, J (2019): Monitoring evidence on overall survival benefits of anti-cancer drugs approved by the European Medicines Agency between 2009 and 2015. European Journal of Cancer. (110): 1-7. DOI: 10.1016/j.ejca.2018.12.026
- Dillinger T, Sheibani-Tezerji R, Pulverer W, Stelzer I, Hassler MR, Scheibelreiter J, et al. Identification of tumor tissue-derived DNA methylation biomarkers for the detection and therapy response evaluation of metastatic castration resistant prostate cancer in liquid biopsies. Mol Cancer. 2022 Jan;21:7. DOI: 10.1186/s12943-021-01445-0